Oncternal Therapeutics Inc Forecast, price target & analysts
Oncternal Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Oncternal Therapeutics Inc Classifications & Recommendation:
Oncternal Therapeutics Inc Price Target
| Target Price | $2.04 |
| Price | $0.53 |
| Potential |
287.39%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Oncternal Therapeutics Inc 2026 .
The average Oncternal Therapeutics Inc target price is $2.04.
This is
287.39%
register free of charge
$2.10
298.78%
register free of charge
$2.02
283.59%
register free of charge
|
|
| A rating was issued by 6 analysts: 0 Analysts recommend Oncternal Therapeutics Inc to buy, 3 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Oncternal Therapeutics Inc stock has an average upside potential 2026 of
287.39%
register free of charge
|
Sales and Margin forecast 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.79 | 1.68 |
| 46.98% | 112.41% | |
| Net Margin | -4,997.47% | -2,138.45% |
| 68.58% | 57.21% |
4 Analysts have issued a sales forecast Oncternal Therapeutics Inc 2024 . The average Oncternal Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Oncternal Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Oncternal Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -13.43 | -12.12 |
| 20.06% | 9.75% | |
| P/E | negative |
4 Analysts have issued a Oncternal Therapeutics Inc forecast for earnings per share. The average Oncternal Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Oncternal Therapeutics Inc...
Current Oncternal Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Brookline Capital |
Locked
➜
Locked
|
Locked | Sep 12 2024 |
| Northland Capital Markets |
Locked
➜
Locked
|
Locked | Sep 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Brookline Capital:
Locked
➜
Locked
|
Sep 12 2024 |
|
Locked
Northland Capital Markets:
Locked
➜
Locked
|
Sep 12 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
